Upgrade to SI Premium - Free Trial

Madrigal Pharma (MDGL)

541.08 -1.53 (0.28%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (10/29/26)

Latest Headlines

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) August 20, 2026 4:05 PM - Globe NewsWire Madrigal Pharmaceuticals adds J&J executive to its board August 12, 2026 8:00 AM - StreetInsider Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors August 12, 2026 8:00 AM - Globe NewsWire Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) August 6, 2026 4:06 PM - Globe NewsWire Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference August 6, 2026 8:01 AM - Globe NewsWire Wolfe Research Upgrades Madrigal Pharmaceuticals (MDGL) to Outperform August 4, 2026 5:07 AM - StreetInsider Madrigal Pharmaceuticals (MDGL) PT Lowered to $962 at Barclays August 3, 2026 6:40 AM - StreetInsider Madrigal Pharma (MDGL) Tops Q2 EPS by 76c July 31, 2026 9:18 AM - StreetInsider H.C. Wainwright Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL) July 31, 2026 6:42 AM - StreetInsider Madrigal Pharmaceuticals (MDGL) PT Lowered to $962 at Barclays July 31, 2026 6:12 AM - StreetInsider Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates July 30, 2026 7:00 AM - Globe NewsWire Madrigal Pharmaceuticals (MDGL) PT Raised to $587 at Canaccord July 29, 2026 6:43 AM - StreetInsider Wells Fargo Starts Madrigal Pharmaceuticals (MDGL) at Overweight July 27, 2026 5:44 AM - StreetInsider Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) July 21, 2026 4:05 PM - Globe NewsWire Madrigal Pharmaceuticals (MDGL) PT Raised to $739 at Citizens Before Q2 Results July 17, 2026 5:02 AM - StreetInsider Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026 July 16, 2026 8:00 AM - Globe NewsWire Madrigal Pharmaceuticals receives three new resmetirom patents July 13, 2026 8:03 AM - StreetInsider Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio July 13, 2026 8:00 AM - Globe NewsWire Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) July 6, 2026 4:05 PM - Globe NewsWire Ribo and Madrigal hit first milestone in siRNA MASH drug program July 2, 2026 3:20 AM - StreetInsider Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH July 1, 2026 9:19 PM - PR NewsWire Piper Sandler Reiterates Overweight Rating on Madrigal Pharmaceuticals (MDGL) June 29, 2026 9:44 AM - StreetInsider Piper Sandler Reiterates Overweight Rating on Madrigal Pharmaceuticals (MDGL) June 24, 2026 9:42 AM - StreetInsider Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) June 22, 2026 4:05 PM - Globe NewsWire Madrigal Pharmaceuticals (MDGL) PT Lowered to $542 at BofA Securities June 11, 2026 5:11 AM - StreetInsider Full Article List